540 related articles for article (PubMed ID: 19737996)
1. Fondaparinux and the management of heparin-induced thrombocytopenia: the journey continues.
Blackmer AB; Oertel MD; Valgus JM
Ann Pharmacother; 2009 Oct; 43(10):1636-46. PubMed ID: 19737996
[TBL] [Abstract][Full Text] [Related]
2. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia.
Efird LE; Kockler DR
Ann Pharmacother; 2006; 40(7-8):1383-7. PubMed ID: 16788093
[TBL] [Abstract][Full Text] [Related]
3. Fondaparinux as a treatment option for heparin-induced thrombocytopenia.
Papadopoulos S; Flynn JD; Lewis DA
Pharmacotherapy; 2007 Jun; 27(6):921-6. PubMed ID: 17542773
[TBL] [Abstract][Full Text] [Related]
4. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia.
Lobo B; Finch C; Howard A; Minhas S
Thromb Haemost; 2008 Jan; 99(1):208-14. PubMed ID: 18217156
[TBL] [Abstract][Full Text] [Related]
5. Fondaparinux (Arixtra(R)), a safe alternative for the treatment of patients with heparin-induced thrombocytopenia?
Badger NO
J Pharm Pract; 2010 Jun; 23(3):235-8. PubMed ID: 21507819
[TBL] [Abstract][Full Text] [Related]
6. Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill.
Wester JP; Leyte A; Oudemans-van Straaten HM; Bosman RJ; van der Spoel JI; Haak EA; Porcelijn L; Zandstra DF
Neth J Med; 2007 Mar; 65(3):101-8. PubMed ID: 17387236
[TBL] [Abstract][Full Text] [Related]
7. [Management of heparin-induced thrombocytopenia].
Aouizerate P; Guizard M
Therapie; 2002; 57(6):577-88. PubMed ID: 12666266
[TBL] [Abstract][Full Text] [Related]
8. Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience.
Grouzi E; Kyriakou E; Panagou I; Spiliotopoulou I
Clin Appl Thromb Hemost; 2010 Dec; 16(6):663-7. PubMed ID: 19825921
[TBL] [Abstract][Full Text] [Related]
9. Fondaparinux-associated heparin-induced thrombocytopenia.
Bhatt VR; Aryal MR; Shrestha R; Armitage JO
Eur J Haematol; 2013 Nov; 91(5):437-41. PubMed ID: 23905719
[TBL] [Abstract][Full Text] [Related]
10. Heparin-induced thrombocytopenia and recent advances in its therapy.
Hassan Y; Awaisu A; Aziz NA; Aziz NH; Ismail O
J Clin Pharm Ther; 2007 Dec; 32(6):535-44. PubMed ID: 18021330
[TBL] [Abstract][Full Text] [Related]
11. Frequent off-label use of fondaparinux in patients with suspected acute heparin-induced thrombocytopenia (HIT)--findings from the GerHIT multi-centre registry study.
Schindewolf M; Steindl J; Beyer-Westendorf J; Schellong S; Dohmen PM; Brachmann J; Madlener K; Pötzsch B; Klamroth R; Hankowitz J; Banik N; Eberle S; Kropff S; Müller MM; Lindhoff-Last E
Thromb Res; 2014 Jul; 134(1):29-35. PubMed ID: 24703295
[TBL] [Abstract][Full Text] [Related]
12. Fondaparinux: does it cause HIT? Can it treat HIT?
Warkentin TE
Expert Rev Hematol; 2010 Oct; 3(5):567-81. PubMed ID: 21083474
[TBL] [Abstract][Full Text] [Related]
13. Treatment of heparin-induced thrombocytopenia with fondaparinux.
Harenberg J; Jörg I; Fenyvesi T
Haematologica; 2004 Aug; 89(8):1017-8. PubMed ID: 15339691
[TBL] [Abstract][Full Text] [Related]
14. Application, tolerance and safety of fondaparinux therapy in a German hospital: a prospective single-centre experience.
Schindewolf M; Scheuermann J; Kroll H; Marzi I; Kaufmann R; Boehncke WH; Ludwig RJ; Lindhoff-Last E
Thromb Res; 2012 Jan; 129(1):17-21. PubMed ID: 21741076
[TBL] [Abstract][Full Text] [Related]
15. The HIT treatment in a cardiac surgery patient.
Anna N; Boyan T; Kader MA; Catherine M; Matthias K
Int J Cardiol; 2010 Oct; 144(3):405-7. PubMed ID: 19324432
[TBL] [Abstract][Full Text] [Related]
16. Delayed-onset HIT caused by low-molecular-weight heparin manifesting during fondaparinux prophylaxis.
Alsaleh KA; Al-Nasser SM; Bates SM; Patel A; Warkentin TE; Arnold DM
Am J Hematol; 2008 Nov; 83(11):876-8. PubMed ID: 18803278
[TBL] [Abstract][Full Text] [Related]
17. Delayed-onset heparin-induced thrombocytopenia type-2 during fondiparinux (Arixtra) therapy.
Modi C; Satani D; Cervellione KL; Cervantes J; Gintautas J
Proc West Pharmacol Soc; 2009; 52():5-7. PubMed ID: 22128408
[TBL] [Abstract][Full Text] [Related]
18. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.
Greinacher A; Alban S; Omer-Adam MA; Weitschies W; Warkentin TE
Thromb Res; 2008; 122(2):211-20. PubMed ID: 18262226
[TBL] [Abstract][Full Text] [Related]
19. The approach to heparin-induced thrombocytopenia.
Linkins LA; Warkentin TE
Semin Respir Crit Care Med; 2008 Feb; 29(1):66-74. PubMed ID: 18302088
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Fondaparinux in Patients With Suspected Heparin-Induced Thrombocytopenia.
Snodgrass MN; Shields J; Rai H
Clin Appl Thromb Hemost; 2016 Nov; 22(8):712-717. PubMed ID: 27179015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
